You are here

FDA Approves Biotest’s BIVIGAM™, an Intravenous Immune Globulin (Human), 10% liquid

Biotest Pharmaceuticals Corporation received approval for Bivigam™ for the treatment of patients with Primary Humoral Immunodeficiency from the U.S. Food and Drug Administration (FDA). Bivigam™ is the first polyspecific intravenous immune globulin manufactured in the U.S. by Biotest Pharmaceuticals Corporation (BPC) at its Boca Raton, Florida facility. This product is being produced for patients in the United States and the company plans to begin commercial shipments shortly.

CLICK HERE to read more

News Category: